Interleukin-6 and Neural Stem Cells: More Than Gliogenesis
IL-6—and depending on the presence of its soluble IL-6R—induces neural stem cells (NSCs) differentiation into astrocytes [via glia progenitor cells (GPC), pathway indicated by green arrows] and neurons [via neuronal progenitor cells (NPC), pathway indicated by red arrows]. During neurodegenerative processes apoptotic neurons release sIL-6R (purple receptor symbols) by shedding, whereas activated astrocytes release IL-6 (red circle). Via trans-signaling they can act on NSCs, which express (as GPCs and NPCs) very low or no IL-6 receptors but the common signaling receptor subunit gp130 (shown as green receptor-dimer symbols) that is used by all members of the IL-6-receptor family (; ). Although EGF and bFGF maintain NSCs' self-renewal, the IL-6–sIL-6R complex overrides those activities mediating NSCs differentiation. In contrast, classical neurotrophic factors such as NGF, BDNF, or NT-3 are unable to overcome EGF signaling. Increased gp130 expression on NSCs/NPCs and IL-6R-NGFR/TRKA (blue receptor symbols) transactivation by IL-6R/gp130 (white dotted line) enhances neuronal differentiation. Differentiated neurons express then various neurotrophic factors for their survival and proper functioning. Inhibiting the glia-differentiation pathway by, for instance, p-STAT-inhibitors (inhibition of nuclear transcription factor activity of p-STATs but not complete down-regulation of their expression) may turn H-IL-6 into an interesting potential therapeutic factor, acting on the MAPK/CREB signaling pathway, for the treatment of neurodegenerative diseases.